AIM ImmunoTech Inc. logo

AIM ImmunoTech Inc. (AIM)

Market Closed
11 Aug, 20:00
AMEX AMEX
$
0. 26
-0.01
-2.3954%
$
921.68K Market Cap
- P/E Ratio
- Div Yield
1.46M Volume
- Eps
$ 0.26
Previous Close
Add Transaction
Day Range
0.25 0.26
Year Range
0.21 2.89
Want to track AIM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Electric Guitar shares resume trading on AIM as company reboots with new board and cash shell strategy

Electric Guitar shares resume trading on AIM as company reboots with new board and cash shell strategy

Electric Guitar PLC (AIM:ELEG) is back on the market. The company's shares will resume trading on AIM Tuesday morning following a major board shake-up and the completion of a fundraising round that sets it up as a so-called “cash shell” - a listed vehicle with no active business but a mandate to acquire one.

Proactiveinvestors | 1 year ago
AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

AIM ImmunoTech Inc. (AIM) Q4 2024 Earnings Call Transcript

AIM ImmunoTech Inc. (NYSE:AIM ) Q4 2024 Earnings Conference Call April 1, 2025 8:30 AM ET Company Participants Thomas Equels - Chief Executive Officer, President and Executive Vice Chairman Conference Call Participants Ed Woo - Ascendiant Capital Markets Operator Hello and welcome to the AIM ImmunoTech Fourth Quarter and Full Year 2024 Update Conference Call and Webcast. As a brief reminder, all participants are currently in a listen-only mode.

Seekingalpha | 1 year ago
Deposed AIM royalty ASOS enjoys a rare week in the sun

Deposed AIM royalty ASOS enjoys a rare week in the sun

Once royalty of the AIM market, with a valuation that once put it on the cusp of the FTSE 100, ASOS PLC's (LSE:ASC)fall from grace has been rapid—and well documented. Earlier this week, its shares were languishing at levels last seen 17 years ago.

Proactiveinvestors | 1 year ago
Jersey Oil and Gas investors to watch keenly as UK Govt's fiscal consultations proceed

Jersey Oil and Gas investors to watch keenly as UK Govt's fiscal consultations proceed

Details will need to be fleshed out, but the UK government has heard the concerns of the North Sea industry, that's what Jersey Oil and Gas PLC (AIM:JOG, OTC:JYOGF) boss Andrew Benitz told investors as Westminster began a round of fiscal consultations. AIM-quoted Jersey and partner Dana Petroleum are poised to develop the Buchan project, which promises additional domestic gas supplies, though the project timeline is in the air amidst uncertainties over the tax regime for the North Sea.

Proactiveinvestors | 1 year ago
KEFI Gold and Copper confirms Tulu Kapi is advancing to project finance greenlight

KEFI Gold and Copper confirms Tulu Kapi is advancing to project finance greenlight

KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) has confirmed its progress toward the close for the Tulu Kapi Gold project financing, ahead of a full project launch. The AIM-quoted mine developer said that its secured lenders have increased project financing facilities to $240 million, from $190 million.

Proactiveinvestors | 1 year ago
Polarean Imaging inks partnership with US outpatient medical imaging firm

Polarean Imaging inks partnership with US outpatient medical imaging firm

Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) is teaming up with SimonMed Imaging, one of America's largest outpatient medical imaging providers. It will see the AIM-quoted firm's Xenon MRI platform delivered across the SimonMed network – starting with a site in Scottsdale, Arizona, later this year.

Proactiveinvestors | 1 year ago
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock?

AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock?

AIM ImmunoTech (AIM) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks | 1 year ago
Deltex Medical shares plunge 50% on proposed AIM cancellation and CEO resignation

Deltex Medical shares plunge 50% on proposed AIM cancellation and CEO resignation

Shares in Deltex Medical Group plc (AIM:DEMG) (AIM: DEMG) fell 50% following the announcement of a proposed delisting from AIM and leadership changes. The company attributed its decision to delist to the high costs of maintaining its AIM listing, estimated at £200,000 annually, representing 10% of its unaudited 2024 revenues of £2.1 million.

Proactiveinvestors | 1 year ago
Orosur Mining Inc Announces Exercise of Warrants

Orosur Mining Inc Announces Exercise of Warrants

Orosur Mining Inc Exercise of Warrants, Issue of Shares and Total Voting Rights LONDON, UNITED KINGDOM / ACCESSWIRE / January 6, 2025 / Orosur Mining Inc. ("Orosur" or "the Company") (AIM/TSXV:OMI), a minerals explorer and developer with projects in Colombia, Argentina and Nigeria, advises that, following an exercise of 179,856 warrants at an exercise price of US$0.0494 (approximately 3.984p) each, the Company will, issue 179,856 new common shares of no par value each ("Common Shares") for a total consideration of US$8,885. Application will be made for the 179,856 Common Shares, which rank pari passu with the existing Common Shares in issue, to be admitted to trading on AIM ("Admission").

Accesswire | 1 year ago
Eden Research's regulatory wins keep coming at breakneck pace

Eden Research's regulatory wins keep coming at breakneck pace

Today's announcement that AIM-listed biopesticides developer Eden Research PLC (AIM:EDEN, OTCQB:EDNSF)'s flagship fungicide product Mevalone has been added to the Organic Input List in Germany didn't happen in a bubble. Rather, it's merely the latest in a long line of regulatory wins secured by the company in a couple of short years.

Proactiveinvestors | 1 year ago
SDX Energy shares plunge on London delisting plan

SDX Energy shares plunge on London delisting plan

SDX Energy PLC (AIM:SDX, OTC:SDXEF) shares plunged around 60% in value on Friday as it announced it intends to exit the London Stock Exchange, delisting from AIM to take up private company status. It is a cost-cutting move for the company which previously sold its primary asset, a gas field in Egypt, to retain gas-producing assets in Morocco, and last month secured a $4.5 million refinancing of a convertible loan.

Proactiveinvestors | 1 year ago
Shield Therapeutics ‘on track for 2024' - analyst

Shield Therapeutics ‘on track for 2024' - analyst

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF)'s proposed $10 million equity agreement with AOP Health International Management “should provide some much-needed breathing room” for the AIM-listed pharma group, said Stifel analysts. “This, along with the business looking to lower its cost base by circa 10%, will help strengthen the balance sheet and support achieving cash flow breakeven by 2025 year-end,” they stated, adding that the company is “on track for 2024”.

Proactiveinvestors | 1 year ago
Loading...
Load More